Risk of mortality among older adults hospitalized for COVID-19 with and without vaccination in Mexico
##plugins.themes.themeEleven.article.main##
Palabras clave
Mortality, COVID-19, Aged, Vaccines, Risk Assessments
Resumen
Background: COVID-19 mortality increases exponentially with age, with age being the main predictor of fatal outcomes. In older adults, susceptibility to infections is associated
with immunosenescence. The SARS-CoV-2 vaccines approved for emergency use were authorized based on interim analyses of phase III clinical trials, which demonstrated
acceptable efficacy and safety in the context of the pandemic. However, the efficacy observed under real-life conditions may differ from theoretical efficacy due to population
heterogeneity.
Objective: This study aimed to evaluate the risk of COVID-19–related mortality in hospitalized older adults with or without vaccination during the pandemic.
Material and methods: A cross-sectional study was designed to evaluate the risk of COVID-19–related mortality in hospitalized older adults with or without vaccination. This study used patient records from a Mexican Social Security Institute (IMSS) hospital in Aguascalientes, Mexico. The study included 1516 adults aged 60 years or older who were hospitalized with COVID-19 between January 2021 and March 2022.
Results: The COVID-19 mortality rate in hospitalized older adults was 48.4%. Mortality was 16% higher in men than in women. Multivariate analysis showed that the risk of a vaccinated older adult dying from COVID-19 is 34% lower than that of an unvaccinated older adult (OR = 0.66; 95% CI: 0.52 to 0.85).
Conclusions: The study demonstrates the importance of older adults receiving the COVID-19 vaccine to reduce their risk of mortality.
Referencias
1. Phillips SP, Carver LF. Greatest Risk Factor for Death from COVID-19: Older Age, Chronic Disease Burden, or Place of Residence? Descriptive Analysis of Population-Level Canadian Data. Int J Environ Res Public Health. 2023;20(24):7181. DOI: 10.3390/ijerph20247181.
2. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43–50 (2022). DOI:10.1126/science.abm3425.
3. Rodríguez-Maldonado AP, Vázquez-Pérez JA, Cedro-Tanda A, Taboada B, Boukadida C, Wong-Arámbula C, et al. Emergence and spread of the potential variant of interest (VOI) B.1.1.519 of SARS-CoV-2 predominantly present in Mexico. Arch Virol. 2021;166(11):3173–7. DOI:10.1007/s00705-021-05208-6.
4. Taboada B, Zárate S, García-López R, Muñoz-Medina JE, Sanchez-Flores A, Herrera-Estrella A, et al. Dominance of Three Sublineages of the SARS-CoV-2 Delta Variant in Mexico. Viruses. 2022;14(6). DOI:10.3390/v14061165
5. Flores-Alanis A, Delgado G, Espinosa-Camacho LF, Rodríguez-Gómez F, Cruz-Rangel A, Sandner-Miranda L, et al. Two Years of Evolutionary Dynamics of SARS-CoV-2 in Mexico, With Emphasis on the Variants of Concern. Front Microbiol. 2022;13. DOI: 10.3389/fmicb.2022.886585.
6. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. 2020;383(27):2603–15. DOI:10.1056/NEJMoa2034577.
7. Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. The Lancet 2021;397(10275):642–3. DOI 10.1016/S0140-6736(21)00191-4.
8. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine. 2021;384(5):403–16. DOI:10.1056/NEJMoa2035389
9. Gobierno de México. Política nacional rectora de vacunación contra el SARS-CoV-2 para la prevención de la COVID-19 en México. Available from: https://vacunacovid.gob.mx/documentos/politica-nacional-rectora-de-vacunacion-contra-el-sars-cov-2-para-la-prevencion-de-la-covid-19-en-mexico-documento-rector/ 10.
10. Shah SM, Alsaab HO, Rawas-Qalaji MM, Uddin MN. A Review on Current COVID-19 Vaccines and Evaluation of Particulate Vaccine Delivery Systems. Vaccines (Basel). 2021;9(10):1086. DOI:10.3390/vaccines9101086
11. Secretaria de Salud, Subsecretaría de Prevención y Promoción de Salud. INFORME INTEGRAL DE COVID-19 EN MÉXICO. Mexico City; 2023 Dec. Available from: https://epidemiologia.salud.gob.mx/gobmx/salud/documentos/covid19/Info-04-23-Int_COVID-19.pdf.
12. Lee SW, Ma D, Davoodian A, Ayutyanont N, Werner B. COVID-19 vaccination decreased COVID-19 hospital length of stay, in-hospital death, and increased home discharge. Prev Med Rep. 2023;102152. DOI:10.1016/j.pmedr.2023.102152.
13. Weigert M, Beyerlein A, Katz K, Schulte R, Hartl W, Küchenhoff H. Vaccine-induced or hybrid immunity and COVID-19-associated mortality during the Omicron wave. Dtsch Arztebl Int. 2023;120(13):213-220. DOI:10.3238/arztebl.m2023.0051.
14. Cegolon L, Pol R, Simonetti O, Larese Filon F, et al. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life. Pharmaceuticals. 2023;16(5):721. DOI:10.3390/ph16050721.
15. Seppälä E, Dahl J, Veneti L, Rydland KM, Klüwer B, Rohringer A, et al. Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023. Vaccine. 2024;42(3):620–8. DOI:10.1016/vaccine.2023.12.050.
16. Navarrete-Mejía P, Parodi JF, Runzer-Colmenares FM, et al. Covid 19, mortalidad en adulto mayor y factores asociados. Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo. 2022;15(2):247–51. DOI:10.35434/rcmhnaaa.2022.152.1158.
17. Hippisley-Cox J, Coupland CA, Mehta N, Keogh RH, Diaz-Ordaz K, Khunti K, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ. 2021 Sep;374:n2244. DOI:10.1136/bmj.n2244.
18. López-Campos JL, Quintana Gallego E, Carrasco Hernández L. Status of and strategies for improving adherence to COPD treatment. Int J Chron Obstruct Pulmon Dis. 2019; 14:1503–15. DOI:10.2147/COPD.S170848.
19. Wu N, Joyal-Desmarais K, Ribeiro PAB, Vieira AM, Stojanovic J, Sanuade C, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir Med. 2023;11(5):439–52. DOI:10.1016/S2213-2600(23)00015-2.
20. Bajči M, Lendak D, Ristić M, Drljača M, Brkić S, Turkulov V, et al. COVID-19 Breakthrough Infections among Patients Aged ≥65 Years in Serbia: Morbidity and Mortality Overview. Vaccines (Basel). 2022;10(11):1818. DOI:10.3390vaccines10111818.
21. Johnson AG, Linde L, Ali AR, DeSantis A, Shi M, Adam C, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(6):145–52. DOI:10.15585/mmwr.mm7206a3.
22. Cruz MC, Nascimento-Carvalho CM. The early evolution of COVID-19 incidence and mortality among people aged under 80 years or 80 years and above after COVID-19 vaccine implementation in the state of Bahia, Brazil. Vaccine. 2022;40(50):7191–4. DOI:10.1016/j.vaccine.2022.10.059.
23. Lopez-Doriga Ruiz P, Gunnes N, Michael Gran J, et al. Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway. Vaccine. 2023;41(2):323–32. DOI:10.1016/j.vaccine.2022.10.085.
24. Domínguez-Ramírez L, Sosa-Jurado F, Díaz-Sampayo G, et al. Age and Comorbidities as Risk Factors for Severe COVID-19 in Mexico, before, during and after Massive Vaccination. Vaccines (Basel). 2023;11(11):1676. DOI:10.3390/vaccines11111676.
25. Gokce A, Hatipoglu M, Akboga S, et al. The Effect of COVID-19 Vaccines on Pneumothorax in Geriatric Patients Hospitalized in Intensive Care Unit Due to COVID-1. Acta Clin Croat. 2022;61(4):655-660. DOI:10.20471/acc.2022.61.04.12.
26. Radomyslsky Z, Kivity S, Lidar S, Bentur N, Korn L, et al. Association between COVID-19 vaccination and critical outcomes among older adults with dementia: a comparative cohort study. Front Public Health. 2023;11:1281266. DOI:10.3389/fpubh.2023.1281266.
27. Hoxha I, Agahi R, Bimbashi A, et al. Higher COVID-19 Vaccination Rates Are Associated with Lower COVID-19 Mortality: A Global Analysis. Vaccines (Basel). 2022;11(1):74. DOI:10.3390/vaccines11010074.
28. Agostini E, Bloise F, Tancioni M. Vaccination policy and mortality from COVID-19 in the European Union. Econom J. 2024;27(2):299–322. DOI:10.1093/ectj/utae005.
29. Teo SP. Review of COVID-19 Vaccines and Their Evidence in Older Adults. Ann Geriatr Med Res. 2021;25(1):4–9. DOI:10.4235/agmr.21.0011.
30. Sharma E, Revinipati S, Bhandari S, et al. Efficacy and Safety of COVID-19 Vaccines—An Update. Diseases. 2022;10(4):112. DOI:10.3390/diseases10040112.
31. Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. COVID‐19 vaccines mix‐and‐match: The concept, the efficacy and the doubts. J Med Virol. 2022;94(4):1294–9. DOI:10.1002/jmv.27463.
##plugins.themes.themeEleven.article.sidebar##
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Los autores conservan sus derechos de autor y otorgan a la Revista Médica del IMSS el derecho de primera publicación. Los artículos se distribuyen bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional, que permite su difusión siempre que se reconozca al autor y la fuente original.